Core Viewpoint - The stock price of Reap Bio fell by 2.00% on September 22, 2023, with a current price of 21.51 CNY per share and a market capitalization of 9.997 billion CNY [1] Group 1: Stock Performance - Reap Bio's stock has increased by 18.99% year-to-date, but has decreased by 2.14% in the last five trading days and 8.39% over the last 20 days [2] - The stock has shown a 10.76% increase over the past 60 days [2] Group 2: Company Overview - Reap Bio, established on August 2, 2001, and listed on September 17, 2010, is located in the Tianjin Free Trade Zone and specializes in veterinary biological products, chemical drugs, biological agents, and animal health products [2] - The company's main business revenue composition is 77.95% from animal health and 22.05% from the pet supply chain [2] - Reap Bio is classified under the agricultural and animal health industry, with concepts including avian influenza drugs, pet economy, raw materials, synthetic biology, and investments in the New Third Board [2] Group 3: Financial Performance - For the first half of 2025, Reap Bio achieved a revenue of 1.708 billion CNY, representing a year-on-year growth of 55.37%, and a net profit attributable to the parent company of 257 million CNY, up 61.19% year-on-year [2] - Since its A-share listing, Reap Bio has distributed a total of 1.371 billion CNY in dividends, with 462 million CNY distributed over the last three years [3] Group 4: Shareholder Information - As of June 30, 2025, Reap Bio had 26,000 shareholders, with an average of 12,883 circulating shares per person [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Guotai CSI Livestock Breeding ETF, with notable changes in their holdings [3]
瑞普生物跌2.00%,成交额9734.56万元,主力资金净流出402.84万元